Nitrergic system NO/cGMP Pitx3 deficient aphakia mice FosB Histone3 Molsidomine Zaprinast Striatum Nitric oxide (NO), a gaseous messenger molecule synthesized by nitric oxide synthase (NOS), plays a pivotal role in integrating dopamine transmission in the basal ganglia and has been implicated in the pathogenesis of Parkinson disease (PD). To study the role of the nitrergic system in L-DOPA-induced dyskinesia (LID), we assessed the effect of the pharmacological manipulation of NO levels and NO/cyclic guanosine monophosphate (cGMP) signaling on LID in the Pitx3 −/− aphakia mouse, a genetic model of PD. To evaluate the effect of decreased NO signaling on the development of LID, Pitx3 −/− mice were chronically treated with L-DOPA and 7-nitroindazole (7-NI, a neuronal NOS inhibitor). To evaluate its effect on the expression of established LID, 7-NI was administered acutely to dyskinetic mice. The chronic 7-NI treatment attenuated the development of LID in the Pitx3 −/− mice, and the sub-acute 7-NI treatment attenuated established dyskinesia without affecting the beneficial therapeutic effect of L-DOPA. Moreover, 7-NI significantly reduced FosB and pAcH3 expression in the acutely and chronically L-DOPA-treated mice. We also examined how increasing NO/cGMP signaling affects LID expression by acutely administering molsidomine (an NO donor) or zaprinast (a cGMP phosphodiesterase 5-PDE5 inhibitor) before L-DOPA in mice with established dyskinesia. Paradoxically, the administration of either of these drugs also significantly diminished the expression of established LID; however, the effect occurred at the expense of the antiparkinsonian L-DOPA properties. We demonstrate that targeting the NO/cGMP signaling pathway reduces dyskinetic behaviors and molecular markers, but only the 7-NI treatment preserved the antiparkinsonian effect of L-DOPA, indicating that NOS inhibitors represent a potential therapy to reduce LID.
Introduction
Parkinson disease (PD) is a neurodegenerative disease with both genetic and acquired etiologies. It is characterized by the degeneration of the dopaminergic neurons of the substantia nigra and a decrease of dopamine (DA) in the dorsal striatum (Dauer and Przedborski, 2003) . Despite the progress in PD research, current treatment focuses on dopamine replacement therapy through the administration of L-3,4-dihydroxyphenylalanine (L-DOPA). However, repeated treatment with L-DOPA is associated with adverse effects, including a reduction in drug efficacy ("wearing off" and "on-off" fluctuations) and the onset of dyskinesia. L-DOPA-induced dyskinesia (LID) is characterized by excessive and abnormal purposeless movements, which interfere with physiological motor activity. The prevalence of LID in PD patients increases with L-DOPA treatment duration, and once it develops, the LID severity increases over time. This LID can be debilitating and represents a major disadvantage of continued L-DOPA therapy (Gerlach et al., 2011; Jankovic, 2005; Prashanth et al., 2011) .
Despite extensive investigation, the mechanisms underlying LID are not completely understood. Several lines of evidence have associated dyskinesia with the expression of FosB, phosphorylation of ERK1/2, and the phosphoacetylation of histone 3 (H3) (Andersson et al., 1999; Cenci and Konradi, 2010; Murer and Moratalla, 2011; Pavón et al., 2006; Santini et al., 2007; Westin et al., 2007) . These molecular markers of dyskinesia require the D1, but not the D2, dopamine receptor (Darmopil et al., 2009) . A wide range of other neurotransmitter systems and molecular mechanisms have been proposed to participate in the pathogenesis of dyskinesia, including glutamate, serotonin, adenosine, noradrenaline, and the cannabinoid receptor (González-Aparicio and Moratalla, 2014; Huot et al., 2013; Iravani and Jenner, 2011) , but their precise contributions to LID remain less well understood. A growing body of evidence also suggests that nitric oxide (NO) plays a role in the maintenance of LID (Del Bel et al., 2005; Padovan-Neto et al., 2011) .
The gaseous signaling molecule NO is produced by a subclass of interneurons containing the neuronal NO synthase (nNOS). NO activates the secondary messenger cyclic guanosine monophosphate (cGMP) through activation of soluble guanyl cyclase and plays a crucial role in Neurobiology of Disease 73 (2015) [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] 
